Our News

Life in the Fastlane

How a Partnership between the FDA and Organ-on-a-Chip Developers Has the Potential to Fast-track Drug Development From a small discovery in a research lab to a capsule on a pharmacist’s shelf – the path of drug development is a long one. Whilst scientists discover or...

read more

CN Bio and Imperial College London Collaboration

CN Bio and Imperial College London collaborate to identify novel treatments for alcoholic hepatitis. CN Bio’s Liver-on-Chip technology to define underlying disease mechanisms and screen therapeutic targets. CN Bio, a leading cell culture company, that has developed...

read more

NASH Drug Discovery Service Launched at AASLD

Leading bioengineering company CN Bio has launched a fee for service program providing Human Organ-on-Chip data to scientists studying non-alcoholic steatohepatitis (NASH) therapeutics. CN Bio launched the program at the American Association for the Study of Liver...

read more
About CN Bio

CN Bio is a leading bioengineering company specialising in single and multi-organ microphysiological systems and innovative lab technologies. We aim to provide systems that generate clinically translatable data that can enhance the development of tomorrow’s medicines.

As an EOE employer, CN Bio will not discriminate in its employment practices due to an applicant’s race, color, religion, sex, national origin, sexual orientation, gender identity, disability or veteran status.